Protagonist Therapeutics Inc (PTGX) Expected to Post Q1 2018 Earnings of ($0.13) Per Share
Protagonist Therapeutics Inc (NASDAQ:PTGX) – Analysts at Leerink Swann issued their Q1 2018 earnings per share estimates for Protagonist Therapeutics in a note issued to investors on Thursday. Leerink Swann analyst J. Schwartz anticipates that the company will post earnings of ($0.13) per share for the quarter. Leerink Swann also issued estimates for Protagonist Therapeutics’ Q2 2018 earnings at ($0.27) EPS, Q3 2018 earnings at ($0.52) EPS, Q4 2018 earnings at $0.29 EPS, FY2018 earnings at ($0.61) EPS and FY2019 earnings at ($1.54) EPS.
A number of other equities analysts have also recently issued reports on the company. Stifel Nicolaus started coverage on Protagonist Therapeutics in a report on Monday, January 29th. They issued a “buy” rating and a $32.00 target price for the company. BidaskClub downgraded shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Zacks Investment Research downgraded shares of Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 4th. Finally, BMO Capital Markets restated an “outperform” rating and set a $42.00 price objective (down previously from $44.00) on shares of Protagonist Therapeutics in a research report on Thursday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $32.25.
Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Wednesday, March 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.19. The company had revenue of $11.28 million during the quarter, compared to analyst estimates of $8.75 million.
In other Protagonist Therapeutics news, insider Richard S. Shames sold 3,529 shares of the company’s stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $20.50, for a total transaction of $72,344.50. Following the completion of the sale, the insider now directly owns 3,529 shares of the company’s stock, valued at $72,344.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Dinesh V. Ph D. Patel sold 1,790 shares of the company’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $19.55, for a total transaction of $34,994.50. Following the sale, the insider now directly owns 192,227 shares of the company’s stock, valued at $3,758,037.85. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,944 shares of company stock valued at $319,839. 15.50% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the business. Bank of Montreal Can increased its holdings in shares of Protagonist Therapeutics by 1,086.0% during the 4th quarter. Bank of Montreal Can now owns 5,930 shares of the company’s stock valued at $123,000 after purchasing an additional 5,430 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Protagonist Therapeutics by 60.8% during the 3rd quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock valued at $169,000 after purchasing an additional 3,617 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of Protagonist Therapeutics by 71.4% during the 2nd quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock valued at $183,000 after purchasing an additional 6,757 shares in the last quarter. California State Teachers Retirement System increased its holdings in shares of Protagonist Therapeutics by 8.5% during the 2nd quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in shares of Protagonist Therapeutics during the 4th quarter valued at approximately $197,000. 57.77% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Protagonist Therapeutics Inc (PTGX) Expected to Post Q1 2018 Earnings of ($0.13) Per Share” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/03/12/protagonist-therapeutics-inc-ptgx-expected-to-post-q1-2018-earnings-of-0-13-per-share.html.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.